FOSTER CITY, Calif., March 12, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment ...

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

Gilead Sciences has shored up its antibody-drug conjugate pipeline by licensing a candidate from German biotech Tubulis in a deal worth up to $415 million. The agreement includes an upfront ...

In a phase 2 trial, an antiretroviral combination developed by Gilead Sciences and MSD suppressed HIV with a single weekly oral dose, raising the hope of a new treatment option for patients.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

**NM signifies a non meaningful value. A dash signifies the data is not available.

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

“The Good Daughter” limited series adaptation at Peacock has added four new series regulars, Variety has learned. Olivia Williams (“Dune: Prophecy,” “The Father”), Michael Dorman ...